What OCA is used for and who it suits

Fresh osteochondral allograft (OCA) transplantation is designed for a specific and often frustrating situation: a focal but large or complex defect in the knee cartilage that has either failed earlier repair attempts or is simply too extensive for techniques such as OATS, AMIC, or MACI to address adequately.

The procedure works by transplanting a plug of donor bone and cartilage — sized and shaped to match the damaged area — into the patient's knee in a single operation. Because the donor cartilage comes ready-made with its own living cells embedded in the extracellular matrix, there is no need for cell culture or a second surgery. The transplanted bone integrates with the recipient bone within roughly 6–12 weeks, while the surface cartilage, protected within its matrix, survives without triggering immune rejection.

OCA sits at the cartilage restoration stage of the treatment pathway — after conservative management and any biologic or injection support have been tried, but well before joint replacement becomes the conversation. It is most commonly indicated for post-traumatic defects, osteochondritis dissecans (OCD), and cases where autograft tissue would be insufficient due to defect size, typically 2 cm² or greater and sometimes extending to full condyle resurfacing.

What OCA is not suited for is equally important. Diffuse or end-stage osteoarthritis is a contraindication; the target is a focal lesion within an otherwise viable, structurally sound joint. Significant malalignment also needs to be corrected — either before or alongside the procedure — for the graft to have a realistic chance of surviving long-term.

Graft survival rates: what the evidence shows

Survival figures from published series point to durable outcomes across all three commonly reported time horizons:

• 5 years: approximately 82–86% of grafts remain functional. A prospective series of 160 femoral condyle cases, at a mean follow-up of 7.7 years, reported 5-year survival of 86.2%; a separate institutional Kaplan-Meier analysis placed the figure at 82.6%.
• 10 years: most series report 78–82% survival at this point. Some institutional datasets record figures closer to 69–70%, reflecting differences in patient selection, defect complexity, and centre case-mix.
• Beyond 20 years: roughly 70% of grafts remain in place and functioning, based on long-term institutional cohort data — the thinnest part of the evidence base, but broadly consistent across the cohorts that have reached this horizon.

One caveat applies to all these figures: no randomised controlled trials exist. Every estimate comes from prospective case series, systematic reviews, and registry analyses. A 2023 systematic review confirmed good long-term survivorship up to 20 years, while explicitly noting the absence of RCT-level evidence.

The spread in reported rates — 10-year figures ranging from roughly 69% to 91% across published series — reflects genuine variation in the populations studied. Most published data come from high-volume specialist centres with carefully selected patients, which may make the headline survival figures more favourable than those seen in broader clinical practice. Defect complexity, prior surgery, and patient characteristics all contribute to this range, and those factors are explored in the section that follows.

Patient and defect factors that affect outcome

Several characteristics on the patient's side — and the defect's — consistently shift the odds in one direction or another. Understanding them helps frame the conversation with a specialist rather than rule anything in or out.

Patient-related factors

BMI and weight carry particular weight in the evidence. A BMI of 30 kg/m² or above is independently associated with roughly double the risk of graft failure, making weight management before surgery a meaningful and modifiable lever for suitable candidates.

Age is significant but nuanced. Patients under 30 with a single focal lesion represent the most favourable profile, with survival figures approaching 99% in some series; age 30 and above is independently associated with elevated failure risk, though age alone rarely determines candidacy.

Underlying diagnosis shapes expectations substantially. Post-traumatic defects and osteochondritis dissecans (OCD) outperform degenerative-disease presentations — early or established osteoarthritis as the primary driver is associated with considerably lower success rates.

Surgical history is one of the clearest predictors. Longer symptom duration before surgery and a greater number of prior knee procedures each independently predict failure. The contrast is concrete: OCA performed as a rescue procedure after failed microfracture achieves a 10-year survival of approximately 61–82%, noticeably below the figures seen when OCA is the primary intervention. This is one reason the evidence points toward earlier consideration of OCA when defect size and complexity suggest it is appropriate.

Defect-related factors

Defects larger than 8 cm², bipolar lesions (where opposing joint surfaces are both involved), and patellar location are all associated with higher failure and reoperation rates compared with isolated single condyle defects. These structural features do not necessarily exclude a patient from OCA, but they inform realistic expectations and the level of specialist experience the procedure demands.

Donor factors and the biological window for success

Behind the scenes of every OCA transplant sits a biological clock. The cartilage cells (chondrocytes) within the donor graft must remain alive for the transplant to integrate — and they begin to die off from the moment of procurement. Published data show that viability drops noticeably after Day 14 and falls below the accepted threshold of roughly 70% viable cells by Day 28. This is why tissue banks and surgeons work within a standard implantation window of 15 to 28 days post-procurement: too early risks inadequate processing and matching; too late risks a graft whose cartilage cells can no longer sustain integration.

Within that 15–28 day window, the timing of implantation was not independently associated with failure in multivariate analysis — so a graft used on Day 18 versus Day 25 does not, in itself, shift the outcome once other variables are accounted for. Donor-to-recipient sex mismatch similarly did not emerge as an independent predictor of failure.

Donor age is a different matter. Older donor age is associated with graft failure, and the association reaches statistical significance specifically in female recipients (p=0.020), though the biological mechanism behind this sex-specific finding is not yet fully established. The evidence on donor characteristics is thinner and more nuanced than on the patient-factor side, and this area remains an active focus of investigation.

Two further biological stresses are worth noting: proinflammatory cytokines already present in the joint environment, and the mechanical loading that occurs during surgical insertion, both adversely affect chondrocyte metabolism at the time of implantation — a reminder that the graft's journey does not end at the moment of procurement.

How rehabilitation and patient engagement shape survival

Of all the factors that determine whether an OCA transplant succeeds, post-operative engagement is the one patients have the most direct control over — and the evidence for its impact is striking.

A 2024 study found that patients enrolled in a structured behavioural health programme (BHP) achieved a 2-year graft survival rate of 91.4%, compared with 68.2% among those who were not enrolled. Non-enrolled patients were 2.8 times more likely to experience graft failure within two years, after adjusting for BMI, sex, age, and tobacco use. The programme involved psychologist-led screening, structured education, and active post-operative support — not intensive rehabilitation in isolation, but a broader framework of guided engagement. This is a single dataset, and the finding warrants replication; the effect size is, however, large enough to take seriously alongside any clinical variable.

The bone integration phase — roughly the first 6 to 12 weeks after surgery — is the period when strict protocol compliance matters most. During this window the donor bone is consolidating with the recipient site, and premature loading or departures from the prescribed rehabilitation plan may jeopardise that process before it is complete.

For patients in the planning stage, a practical question to put to any prospective specialist is what structured rehabilitation and post-operative support is included as part of the care pathway — not just the surgical technique itself.

Functional recovery and return to sport

For active patients, the structural survival figures in the preceding sections matter less than a more immediate question: will the knee work well enough to return to sport or physical activity?

Published series in athletic populations report return-to-sport rates ranging from 59% to 91% — a wide band that reflects genuine differences between patients, not imprecision in the data. Defect complexity, the number of prior knee procedures, and adherence to rehabilitation each pull the figure up or down, which is why no single number honestly represents the typical outcome. The mean time to return in the same series ranged from 9 to 16 months — a timeline measured in seasons, not weeks.

Beyond athletic series, broader cohort data offer a useful anchor for patients who want to return to recreational activity rather than competitive sport. At a mean follow-up of around six years, approximately 75% of OCA recipients had returned to sport or recreational activity, and around 71% rated their knee function as very good to excellent.

Graft failure in athletic populations occurred in 0–10.8% of cases across reviewed series, and significant improvements in pain scores (VAS reductions of 3.7 to 5.7 points) and IKDC functional scores (improvements of 25 to 33 points) were consistently reported alongside return-to-sport data.

Patients who have not returned to their previous activity level by 18 to 24 months should raise this with their treating specialist. A plateau at that point may warrant review of the rehabilitation approach or imaging assessment — it is not, in itself, evidence of graft failure, but it warrants clinical attention rather than continued waiting.

Taken together, the evidence supports a cautiously optimistic picture for motivated, well-selected patients: most return to meaningful physical activity, outcomes have improved as patient selection has become more precise, and the procedure has a durable track record now spanning more than two decades of follow-up data.